Resources
Patient Journey
Pretreatment Assessment Guide
AASLD/IDSA guidance on HCV screening, diagnosis, treatment, and management
On-Treatment Monitoring Guide
AASLD/IDSA guidance for monitoring patients with diabetes or on anticoagulants
Posttreatment Follow-Up Guide
Guidance on follow-up for patients who have been treated for HCV infection, based on treatment success
Awareness
Extrahepatic Manifestations in HCV Infection
An overview on extrahepatic manifestations among patients with HCV with an emphasis on people who use drugs
Anatomy of the Liver
Animation and handout on the structure and function of the liver
Fibrosis and Cirrhosis of the Liver
A summary of the causes of fibrosis, how it occurs, the different stages, and what cirrhosis is
HCV Screening & Assessments
HCV Screening Guide
An overview of the AASLD/IDSA guidelines for the screening and diagnosis of patients with hepatitis C
HCV Screening for Infants and Children
An overview of the guidelines for the screening and diagnosis of infants and children with hepatitis C
Pretreatment Laboratory Assessments
AASLD/IDSA recommendations for pretreatment assessments following an HCV diagnosis
Hepatitis B Reactivation Guide
HBV reactivation causes, complications, assessments, and treatment considerations for patients with HCV/HBV coinfection
Assessing Liver Damage Caused by HCV Infection: Common Laboratory Tests
Assessments to be conducted within 6 months prior to starting HCV treatment
Liver Damage Assessments to Identify Patients for Simplified HCV Treatment
Noninvasive techniques that can be used to assess liver damage
Identifying and Managing Patients With Cirrhosis
The differences between compensated and decompensated cirrhosis, how to measure the severity, and AASLD/IDSA guidelines
Identifying and Managing Patients Without Cirrhosis
The degree of hepatic fibrosis is key to determining the initial and follow-up management of patients
HCV Management
Specialty Pharmacy Brochure
Essential information on specialty pharmacies and how to collaborate with them effectively
HCV Reinfection Rates in People Who Inject Drugs
Information on HCV reinfection rates and risk reduction strategies for people who inject drugs
